Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Rezolute, Inc. - Common Stock (NV) (NQ:RZLT)

2.690 -0.050 (-1.82%)
Streaming Delayed Price Updated: 12:57 PM EST, Dec 26, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Rezolute, Inc. - Common Stock (NV)

< Previous 1 2 3 Next >
News headline image
UPCOMING DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute
From Faruqi & Faruqi, LLP
Via Business Wire
News headline image
REZOLUTE INVESTIGATION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of RZLT
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
Hagens Berman Investigating Rezolute, Inc. (RZLT) as Shares Tank 90% Amid Lead Asset Trial Failure
From Hagens Berman
Via Business Wire
News headline image
Rezolute, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – RZLT
From DJS Law Group
Via Business Wire
News headline image
INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute
From Faruqi & Faruqi, LLP
Via Business Wire
News headline image
Rezolute Announces Phase 3 sunRIZE Study Results in Congenital Hyperinsulinism
From Rezolute, Inc.
Via GlobeNewswire
News headline image
Rezolute Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Rezolute, Inc.
Via GlobeNewswire
News headline image
Rezolute Reports First Quarter Fiscal 2026 Financial Results and Provides Business Update
From Rezolute, Inc.
Via GlobeNewswire
News headline image
Rezolute to Host Virtual Investor Event on Ersodetug Development Program
Webcast scheduled for Monday, November 10 at 12:00 pm EST 
From Rezolute, Inc.
Via GlobeNewswire
News headline image
Rezolute to Participate in Upcoming Investor Conferences
From Rezolute, Inc.
Via GlobeNewswire
News headline image
Rezolute Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Rezolute, Inc.
Via GlobeNewswire
News headline image
Rezolute Reports Fourth Quarter and Full Year Fiscal 2025 Financial Results and Provides Business Update
From Rezolute, Inc.
Via GlobeNewswire
News headline image
Rezolute Announces Alignment with FDA on Streamlined Design for Ongoing Phase 3 Trial of Ersodetug in Tumor Hyperinsulinism
From Rezolute, Inc.
Via GlobeNewswire
News headline image
Rezolute to Participate in Upcoming Investor Conferences
From Rezolute, Inc.
Via GlobeNewswire
News headline image
Rezolute Appoints Seasoned Commercial Executive Sunil Karnawat as Chief Commercial Officer
Experienced commercial and biopharmaceuticals leader to spearhead launch strategy and global market readiness for ersodetug 
From Rezolute, Inc.
Via GlobeNewswire
News headline image
Rezolute to Participate in the BTIG Virtual Biotechnology Conference
From Rezolute, Inc.
Via GlobeNewswire
News headline image
Rezolute Announces Presentation of Participant Baseline Data from its Fully Enrolled Phase 3 Study of Ersodetug in Congenital Hyperinsulinism at the Upcoming Annual Meeting of the Endocrine Society (ENDO 2025)
From Rezolute, Inc.
Via GlobeNewswire
News headline image
Rezolute Announces Completion of Enrollment in the Phase 3 sunRIZE Study of Ersodetug in Patients with Congenital Hyperinsulinism
From Rezolute, Inc.
Via GlobeNewswire
News headline image
Rezolute Reports Third Quarter Fiscal 2025 Financial Results and Provides Business Update
From Rezolute, Inc.
Via GlobeNewswire
News headline image
Rezolute Receives Breakthrough Therapy Designation from FDA for Ersodetug in the Treatment of Hypoglycemia Due to Tumor Hyperinsulinism
From Rezolute, Inc.
Via GlobeNewswire
News headline image
Rezolute to Participate in Upcoming Investor Conferences
From Rezolute, Inc.
Via GlobeNewswire
News headline image
Rezolute, Inc. Announces Closing of Underwritten Offering
From Rezolute, Inc.
Via GlobeNewswire
News headline image
Rezolute Announces Pricing of Offering of $90 Million of Common Stock and Pre-Funded Warrants
From Rezolute, Inc.
Via GlobeNewswire
News headline image
Rezolute Announces Positive Recommendation After Independent Interim Analysis of Phase 3 sunRIZE Study of Ersodetug in Congenital Hyperinsulinism (“HI”)
From Rezolute, Inc.
Via GlobeNewswire
News headline image
Rezolute Announces Appointment of Rare Disease Commercial Leader Erik Harris to its Board of Directors
From Rezolute, Inc.
Via GlobeNewswire
News headline image
Rezolute Reports Second Quarter Fiscal 2025 Financial Results and Provides Business Update
From Rezolute, Inc.
Via GlobeNewswire
News headline image
Rezolute Provides Update on its Phase 3 sunRIZE Study of Ersodetug for the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism
From Rezolute, Inc.
Via GlobeNewswire
News headline image
Rezolute to Participate in the Guggenheim SMID Cap Biotech Conference
From Rezolute, Inc.
Via GlobeNewswire
News headline image
Rezolute Receives Breakthrough Therapy Designation from FDA for Ersodetug in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism
From Rezolute, Inc.
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.